Skip to main content
. 2019 Dec 13;9:19100. doi: 10.1038/s41598-019-55615-8

Figure 2.

Figure 2

Visualization of TGF-β on HIV-1 virions. (a) Flow virometry of virions from blood plasma of infected individual gated on CD36 and CD27. (b) TGF-β+ virions in the population of CD36+ virions. (c) The lack of TGF-β+ virions in the population of CD27+ virions. A representative experiment out of three is presented. (d) Fractions of TGF-β+ on CD36+ and CD27+ virions captured with 2G12/PG9–MNPs as evaluated with flow virometry. Presented are means ± s.e.m. (n = 3). (e) L-TGF-β on virions captured with 2G12/PG9-MNPs. Electron micrograph of a negatively stained preparation. MNPs are marked with white asterisks; L-TGF-β is revealed by 6-nm colloidal gold-labeled secondary antibodies (yellow arrows). Bar: 50 nm (f) Control for specificity of staining. Virions captured with 2G12/PG9-MNPs and incubated with 6-nm colloidal gold-labelled secondary antibodies without primary anti L-TGF-β antibodies. MNPs are marked with white asterisks. Bar: 50 nm (g) CD36, TSP, and LAP proteins present in 2G12/PG9-MNP captured virions. Western blot analysis. A representative experiment out of three is presented. (For full-length gels/blots, see Supplementary Fig. 1). (h) Relative presence of TSP and LAP on captured virions. Average values from three experiments are presented.